Passage Bio
PASG
85 hedge funds and large institutions have $78.4M invested in Passage Bio in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 36 reducing their positions, and 33 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.07% less ownership
Funds ownership: 3.96% → 3.88% (-0.07%)
21% less funds holding
Funds holding: 108 → 85 (-23)
41% less capital invested
Capital invested by funds: $133M → $78.4M (-$54.8M)
44% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 36
58% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$3.74M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$1.92M |
| 3 |
NM
Newtyn Management
New York
|
+$1.45M |
| 4 |
Morgan Stanley
New York
|
+$905K |
| 5 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$738K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.49M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.46M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.49M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$741K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$686K |
PASG Hedge Fund Activity: Q2 2022 in Review
85 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q2 2022, worth a combined $78.4M — down 41% from $133M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of PASG and 14 opened new positions — a net loss of 19 holders — while 36 trimmed existing stakes and 20 added.
The largest buyer was OrbiMed, adding an estimated $3.74M. The largest seller was BlackRock, cutting an estimated $4.49M.
- 85 institutional investors held Passage Bio (PASG) as of Q2 2022, down from 108 in Q1 2022.
- Funds reported $78.4M of Passage Bio stock for Q2 2022, down 41% quarter-over-quarter.
- 14 funds opened new Passage Bio positions in Q2 2022 and 33 closed out, a net change of -19 holders.
- The largest Passage Bio buyer in Q2 2022 was OrbiMed, an estimated $3.74M added.
- The largest Passage Bio seller in Q2 2022 was BlackRock, an estimated $4.49M sold.
Based on aggregated 13F filings for Q2 2022.